Why the study?
Does atrial pacing provide safe and effective therapy in pediatric and young adult patients with sick sinus syndrome?
Does atrial pacing provide safe and effective therapy in pediatric and young adult patients with sick sinus syndrome?
Atrial pacing is a safe and effective therapy for children and young adults with sick sinus syndrome, with transvenous leads showing better operative stimulation thresholds than epicardial leads.
Answers are grounded in this paper and cite their sources.
May support atrial pacing for symptom relief in pediatric sick sinus syndrome; leaves open optimal lead choice and long-term outcomes.
Forty pediatric and young adult patients (1-20 years; mean, 11 years of age) had implantation of atrial demand (AAI) pacemakers over a 5.5 year period. Nineteen were implanted by epicardial technique and 21 transvenously. Standard lithium single chamber pulse generators and standard atrial leads were used. Operative stimulation thresholds were better for transvenous leads than for epicardial (0.75 volts vs. 1.5 volts at 0.5 ms) (p less than 0.05). Pulse width thresholds at a mean of 1.5 years were not significantly different (0.11 ms for transvenous vs. 0.18 for epicardial). No patient developed AV block. Eight patients (four epicardial and four endocardial) required reoperation during the mean 3.5 year follow-up--four because of lead problems and four because of persistent tachycardia. Of the six patients who received an automatic antitachycardia pacemaker, only one had persistent symptoms while seven of eight who received a standard unit continued to have symptoms. Twenty-eight of 29 symptomatic patients without tachycardia became asymptomatic. Atrial pacing appears to be a safe and effective therapy for children with sick sinus syndrome.
No takes yet. Share an insight, caveat, or question.
Gillette et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: